Education
About Us
Working with TipRanks
Follow Us
BioStem Technologies (BSEM)
OTHER OTC:BSEM
BSEM Stock Chart & Stats
$4.83
$0.88(5.85%)
At close: 4:00 PM EST
$4.83
$0.88(5.85%)
Day’s Range― - ―
52-Week Range$3.09 - $15.74
Previous CloseN/A
Volume47.30K
Average Volume (3M)145.61K
Market Cap
$90.68M
Enterprise Value$66.76M
Total Cash (Recent Filing)$27.16M
Total Debt (Recent Filing)$3.39M
Price to Earnings (P/E)6.5
Beta1.84
Next Earnings
Apr 06, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding16,338,436
10 Day Avg. Volume59,286
30 Day Avg. Volume145,613
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)5.54
Price to Sales (P/S)0.75
P/FCF Ratio9.42
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue0.28
Enterprise Value/Gross Profit0.29
Enterprise Value/Ebitda4.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.29
Revenue Forecast (FY)$271.30M
Bulls Say, Bears Say
Bulls Say
High Profitability And Cash GenerationSustained high gross margins and positive operating and free cash flow (FCF/net income ~0.98) indicate the business converts sales to cash efficiently. This durable cash generation supports ongoing R&D, working capital, and strategic investments without relying heavily on external financing.
Conservative Capital StructureVery low leverage provides financial flexibility to fund expansion, absorb reimbursement or pricing shocks, and pursue strategic projects (e.g., facility investments, market entry) while keeping interest burden limited. It reduces refinancing risk over the medium term.
Operational Resilience And Regulated ReadinessConsistent positive adjusted EBITDA across seven quarters, combined with a clean FDA inspection and active expansion into Medicaid and VA channels, demonstrates durable operational control and regulated-market readiness, supporting sustainable commercialization and longer-term revenue opportunities.
Bears Say
Sustained Revenue DeclineMaterial year-over-year and sequential revenue declines point to structural top-line pressure driven by pricing/reimbursement shifts and competitive dynamics. Persistent revenue erosion can undermine scale economics, limit reinvestment capacity, and pressure long-term growth prospects.
Margin Compression And Falling ROEA decline in gross margin alongside a notable drop in ROE suggests emerging margin pressure and reduced capital efficiency. If pricing and reimbursement headwinds persist, profit margins and returns on equity could continue to compress, weakening long-term profitability sustainability.
Slowing Free Cash Flow Growth And Cash DepletionDeclining FCF growth and a falling cash balance—partly due to strategic land acquisition and collection timing—reduce near-term liquidity cushions. Continued FCF deceleration would limit ability to fund expansion or absorb shocks without tapping reserves or raising capital.
BioStem Technologies News
BSEM FAQ
What was BioStem Technologies’s price range in the past 12 months?
BioStem Technologies lowest stock price was $3.09 and its highest was $15.74 in the past 12 months.
What is BioStem Technologies’s market cap?
BioStem Technologies’s market cap is $90.68M.
When is BioStem Technologies’s upcoming earnings report date?
BioStem Technologies’s upcoming earnings report date is Apr 06, 2026 which is in 33 days.
How were BioStem Technologies’s earnings last quarter?
BioStem Technologies released its earnings results on Nov 13, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0 by $0.03.
Is BioStem Technologies overvalued?
According to Wall Street analysts BioStem Technologies’s price is currently Overvalued.
Does BioStem Technologies pay dividends?
BioStem Technologies does not currently pay dividends.
What is BioStem Technologies’s EPS estimate?
BioStem Technologies’s EPS estimate is 0.02.
How many shares outstanding does BioStem Technologies have?
BioStem Technologies has 16,338,436 shares outstanding.
What happened to BioStem Technologies’s price movement after its last earnings report?
BioStem Technologies reported an EPS of $0.03 in its last earnings report, beating expectations of $0. Following the earnings report the stock price went down -3.986%.
Which hedge fund is a major shareholder of BioStem Technologies?
Currently, no hedge funds are holding shares in BSEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioStem Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
BSEM Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.42%
12-Months-Change
Fundamentals
Return on Equity
55.46%
Trailing 12-Months
Asset Growth
-40.12%
Trailing 12-Months
Company Description
BioStem Technologies
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.
BSEM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
BioStem Technologies demonstrated resilience and strategic growth through increased product volume, consistent positive adjusted EBITDA, and strong gross margins. The company successfully expanded into new markets despite facing revenue and cash balance declines due to competitive pricing pressures and strategic investments.View all BSEM earnings summariesTechnical Analysis
Crescent Biopharma
―
Voyager Therapeutics
―
Diamedica Therapeutics
―
Black Diamond Therapeutics
―
Innate Pharma
―